Edition:
United States

People: Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

60.65USD
3:59pm EST
Change (% chg)

$0.66 (+1.10%)
Prev Close
$59.99
Open
$59.74
Day's High
$60.87
Day's Low
$58.67
Volume
232,588
Avg. Vol
327,417
52-wk High
$84.35
52-wk Low
$47.79

Orwin, John 

Mr. John A. Orwin is an Independent Director of Seattle Genetics, Inc. Mr. Orwin has served as Chief Executive Officer and member of the Board of Relypsa, Inc., a publicly-traded commercial-stage pharmaceutical company. Prior to Relypsa, Mr. Orwin served as President and Chief Operating Officer of Affymax, Inc., a biotechnology company, from April 2010 to January 2011, as their Chief Executive Officer from February 2011 through May 2013 and a member of their board of directors from February 2011 to November 2014. From 2005 to April 2010, Mr. Orwin served as Vice President and then Senior Vice President of the BioOncology Business Unit at Genentech, Inc. (now a member of the Roche Group), a biotechnology company, where he was responsible for all marketing, sales, business unit operations and pipeline brand management for Genentech’s oncology portfolio in the United States. From 2001 to 2005, Mr. Orwin served in various executive-level positions at Johnson & Johnson, a life sciences company, overseeing oncology therapeutic commercial and portfolio expansion efforts in the U.S. Prior to such roles, Mr. Orwin held senior marketing and sales positions at various life sciences and pharmaceutical companies, including Alza Corporation (acquired by Johnson & Johnson), Sangstat Medical Corporation (acquired by Genzyme), Rhone-Poulenc Rorer Pharmaceuticals, Inc. (merged with Sanofi-Aventis) and Schering-Plough Corporation (merged with Merck). Mr. Orwin serves as a member of the board of directors of Array BioPharma Inc., a publicly-traded biopharmaceutical company, and served on the board of directors of NeurogesX, Inc., a biopharmaceutical company, until July 2013. Mr. Orwin received an M.B.A. from New York University and a B.A. from Rutgers University.

Basic Compensation

Total Annual Compensation, USD 68,000
Restricted Stock Awards, USD 246,420
Long-Term Incentive Plans, USD --
All Other, USD 233,745
Fiscal Year Total, USD 548,165

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Clay Siegall

8,616,340

Todd Simpson

3,061,800

Jean Liu

2,399,940

Darren Cline

--

Vaughn Himes

2,760,340

Felix Baker

575,165
As Of  30 Dec 2017